With deeps links to the US likely severed, and HSBC’s risk appetite unknown, what does a future without Silicon Valley Bank look like?
As Bridgebio appears to validate FGFR3 as a target in achondroplasia, who else might follow suit?
The next few months will see some important mid-stage Nash results, from Viking, 89Bio, Northsea and others.
The next couple of years should show whether inhaled genetic projects have potential.
Chills in the biopharma M&A market are frequently blamed on the FTC. But is the agency really stopping deals from happening?
Roche’s zinpentraxin alfa is out of the running, but Bristol, Blade, Pliant and others have contenders in the mid-stage idiopathic pulmonary fibrosis pipeline.
The remarkable thing is that these tie-ups are still occurring, so atrocious is their track record.
Ferring's Adstiladrin has joined Keytruda with a US approval, but it might not be the answer doctors are looking for.
A pivotal study of Keytruda’s SC formulation is about to read out, but Roche could get to market first.